NewTimeSpace News:Hong Kong biotech stocks staged another rally on March 6, with 3SBio surging over 10%, Innovent Biologics jumping more than 5%, and Ascentage Pharma-B climbing over 4%. CSOP Hang Seng Biotech ETF (03174.HK) opened up more than 2.5%.

CSOP Hang Seng Biotech ETF (03174.HK), issued by CSOP Asset Management and listed on the Hong Kong Stock Exchange, tracks the Hang Seng Biotech Index. This index fund focuses on leading biotech companies listed in Hong Kong, characterized by high volatility and high beta, making it suitable for investors bullish on innovative drugs, CXO, vaccines, gene therapy and other sub-sectors.

On the policy front, this year's national government work report explicitly listed biopharma as an "emerging pillar industry" at the state level, alongside integrated circuits, aerospace, and low-altitude economy. This marks the first time biopharma has been positioned as a pillar industry in the government work report, sending a strong policy signal to accelerate industrial upgrading.

Notably, "innovative drugs" has been written into the government work report for three consecutive years. The 2024 report first mentioned "innovative drugs," while the 2025 government work report further clarified the commitment to improve drug pricing mechanisms, establish an innovative drug catalog, and support the development of innovative drugs and medical devices.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.